On a more positive note, Novo Nordisk reported positive results from a Phase 2 trial of its next highly promising GLP-1 receptor agonist, amycretin, in Type 2 diabetes. The trial combined a …
Here’s Why Novo Nordisk Stock Popped Today
view original post